CNS PHARMACEUTICALS AG Lists on the Frankfurt Stock Exchange.

NEW YORK -- CNS PHARMACEUTICALS AG, a developer and marketer of Patented Natural Nutraceutical Products, today announced that it has gained a listing on the Frankfurt Stock Exchange under the trading symbol C35 and ISIN# CH0038943467.

CNS has 20,000,000 common shares issued and outstanding. There are no other special shares or share classes.

CNS PHARMACEUTICALS AG, based in Zurich, Switzerland, is the parent Company of its 100%-owned U.S. subsidiary, CNS PHARMACEUTICALS INC.

CNS's Scientific Advisory Board consists of the world renowned scientists of Dr. John Blass and Dr. Robert Shorr. John Blass, MD, Ph.D., was the First Chairman of the Joint Presidential-Congressional Panel on Alzheimer's disease and Related Disorders, he is Professor Emeritus at Weill Medical College of Cornell University, has published over 300 articles and studies on understanding and improving brain function especially for the aging. Robert Schorr, Ph.D. is a scientist and entrepreneur with more than 100 inventions. He has published 150+ technical articles. Dr. Shorr is also a CEO for Cornerstone Pharmaceuticals, which is involved in developing an anti-cancer drug. Dr. Shorr is a highly respected member of the biotechnology and pharmaceutical science community.

Samuel Weisberger, President, believes CNS is on the cutting edge of research and development of a natural supplement to support memory and mental acuity, especially for those over 50 years of age. CNS's patented over-the-counter "flagship" product, MemorA-Z caplets, was developed by Dr. John Blass, and has undergone scientific testing. MemorA-Z is a timely answer to the worldwide concern with maintaining optimal brain output, especially among "baby boomers." It is now ready for promotion and distribution Worldwide.

For more information, visit the Deutche Borse at: http://deutche-boerse.com.

Information presented in this newsletter contain "forward looking statements" within the meaning of section 27A of the Securities act of 1933 and section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects'", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur.